Wegovy Cost: $1,349 US vs $349 on Novo's Own Site (2026)

Key Takeaways

$1,349 list, $349 on the maker's own site. Novo Nordisk lists Wegovy at $1,349.02 per four-week pack while selling the same pen self-pay for $349 on NovoCare (since Nov 2025; new patients pay $199 a month for their first two months on the starting doses, through Dec 31, 2026). The gap is on one company's own pages.
The maker's own prices undercut the list. Novo's $349 cash price and Lilly's $299–449 self-pay Zepbound both sit far below list. Peer-reviewed estimates put a sustainable, profit-inclusive price for semaglutide at a few dollars a month at the diabetes dose (JAMA Network Open) and about $40 in another study (Obesity). It's the system, not the chemistry.
Medicare's July 2026 pilot is real — and conditional. $50 copay for weight-loss use, a first. But temporary (through end-2027), Zepbound is covered only as the KwikPen, and the negotiated $385 Wegovy price starts only in Jan 2027; only about one in three of the biggest employers cover these drugs for weight loss (KFF 2026).
"Just order it abroad" has three problems. FDA says personal importation is illegal in most circumstances, and seizures happen; counterfeit semaglutide reached the regulated supply chain in the US, UK and Brazil (WHO/FDA); and the FDA closed the compounded path in 2025, a move a court declined to block.
The gap is real — and bending. The US spent $71.7B gross on GLP-1 drugs in 2023, but self-pay Wegovy fell to $349, the list halves to $675 in Jan 2027, and Canada approved the first G7 generic semaglutide (an Ozempic copy for diabetes) in April 2026. Ask for the cash price.

Cost Comparison (2026)

Figures from Novo Nordisk's and Eli Lilly's own published prices, NovoCare's self-pay page, NICE's published UK list prices, Denmark's official price register, German pharmacy trade press, KFF coverage surveys, CMS, and peer-reviewed studies. Where a number is reported or still changing, we say so.

Bar chart of the price of Wegovy for one month or one pen, October 2026: Netherlands $206, Switzerland $214, Germany $310 (2025 pharmacy price), Denmark $340, US self-pay $349, US list price $1,349. — One month or one pen. US: Novo Nordisk list price per four-week pack and NovoCare self-pay price. Germany: pharmacy price of the maintenance dose (APOTHEKE ADHOC, March 2025; statutory insurance does not pay). Denmark: top dose (medicinpriser.dk, Oct 2026). Switzerland: public price per pen, BAG Spezialitätenliste. Netherlands: average price of the 2.4 mg pen (four doses), Zorginstituut. USD at ECB rates of October 26, 2026. Made by Wellness Vision from the values in the table below.

Country	Price for one month or one pen	In US dollars	What a patient typically pays
🇺🇸 United States (list)	$1,349.02 per four-week pack	$1,349	Depends on insurance; the maker sells the same pen self-pay for $349
🇩🇰 Denmark	top dose, about $340 (Oct 2026)	$340	—
🇩🇪 Germany	about €277 a month, maintenance dose (pharmacy price, 2025)	$310	Statutory insurance does not pay for Wegovy, so patients pay it themselves
🇨🇭 Switzerland	CHF 176.95 per pen (public price, every strength)	$214	Basic insurance can pay in obesity only with the insurer's prior approval (BMI 35+, or 28+ with weight-related conditions), for at most three years, with a 10% patient share
🇳🇱 Netherlands	€184.35 per 2.4 mg pen (four doses)	$206	Basic insurance does not cover it
🇬🇧 United Kingdom	£73–176 a pack (list price, 2023)	—	The few NHS patients who qualify pay only the £9.90 prescription charge in England

Conversions to US dollars at ECB rates of October 26, 2026, as in the chart. “—”: the article gives no figure for this.

Market	Figure	Context	Source
United States	$1,349/month (list)	Wegovy's US list price is $1,349.02 per four-week pack (Novo Nordisk). But Novo sells the same pen self-pay for $349 on its own site (since Nov 2025; new patients pay $199 a month for their first two months on the starting doses, an offer running through Dec 31, 2026). Zepbound tells the same story: about $1,086 list for the single-dose pen vs Lilly's own $299–449 self-pay price for its vial and KwikPen ($449 tier with on-time refills; $499–699 otherwise).	NovoCare (2026) · LillyDirect (2026) · CMS NADAC (Oct 2026)
Their own site	$349/month (self-pay)	The strangest gap here isn't between countries — it's on one company's own pages. $1,349 list versus $349 cash, same pen, same maker. Paying the cash price is still about $4,500 a year for one prescription (13 four-week packs at $349).	NovoCare self-pay (Nov 2025)
Germany · UK · Denmark	~€277 · £73–176 · ~$340	The same semaglutide costs about €277 a month at the maintenance dose in German pharmacies (after an April 2025 price cut; statutory insurance does not pay for Wegovy, so patients pay it themselves). The UK list price is £73–176 a pack (2023), and the few NHS patients who qualify pay only the £9.90 prescription charge in England. In Denmark, Novo's home country, the top dose costs about $340 (October 2026). In the UK and Denmark it comes as one four-dose pen rather than four single-dose pens. These are mostly the maker's own prices, not negotiated ones; only the NHS gets a confidential discount.	APOTHEKE ADHOC (Mar 2025) · G-BA (Mar 2024) · NICE TA875 · NHS.uk · medicinpriser.dk (Oct 2026)
Switzerland · Netherlands	CHF 176.95 · €184.35 per pen	Two official European prices for Wegovy: Switzerland's Spezialitätenliste lists the Wegovy pen (Multi FixDose, same price at every strength) at CHF 176.95 public price — and, unlike Germany, basic insurance can pay for it in obesity, but only with the insurer's prior approval, for a BMI of 35 or more (28 or more with weight-related conditions), for at most three years, with a 10% patient share. The Dutch Zorginstituut lists the 2.4 mg FlexTouch pen (3 mL, 9.6 mg — four 2.4 mg doses) at an average price of €184.35; basic insurance does not cover it. Austria's reimbursement code does not list Wegovy.	BAG Spezialitätenliste · Zorginstituut (Oct 2026) · Dachverband EKO (Nov 2026)
The catch — coverage	Conditional	A Medicare pilot began July 1, 2026: $50 copay for weight-loss use — a first, but temporary (through end-2027), and for Zepbound it covers only the KwikPen. The negotiated $385 Wegovy price doesn't start until Jan 2027. In 2026 only about one in three of the largest employers covered these drugs for weight loss (down from 43% in 2025), and only 13 state Medicaid programs still did as of January 2026.	CMS Medicare GLP-1 Bridge · CMS negotiated prices (IPAY 2027) · KFF EHBS 2026 · KFF Medicaid (Jan 2026)

We compare what the drug costs, not what anyone should take, switch, or import. Treatment decisions belong with you and a licensed prescriber.

Critical Considerations

Relief arrived in July 2026 — read the fine print

On July 1, 2026, a Medicare pilot began covering Wegovy and the Zepbound KwikPen for weight loss at a $50 copay — the first time Medicare has covered these drugs for weight loss at all. An honest comparison says that loudly. It also says the rest: the pilot is scheduled only through the end of 2027, the negotiated $385 Wegovy price doesn't begin until January 2027, and it does nothing for the employer-coverage gap, where only about one in three of America's largest employers covered these drugs for weight loss in 2026 and only 13 state Medicaid programs still did as of January 2026 (KFF).

The maker's own prices tell the story

Novo Nordisk sells the same semaglutide pen two ways on its own pages: $1,349 list and $349 self-pay. Eli Lilly does the same with tirzepatide: about $1,086 list for the single-dose pen versus $299–449 self-pay for its vial and KwikPen. When a company's own price list spans a four-fold range for the same drug, the list price is a choice, not a cost. Peer-reviewed estimates put a sustainable price, profit included, at $0.89–$4.73 a month at the usual diabetes dose (JAMA Network Open) — far below either list.

The honest math on "just buy it abroad"

Personal importation isn't a legal right — the FDA says it is illegal in most circumstances, and packages can be seized. The counterfeit problem is not hypothetical: fake semaglutide (sold as Ozempic) has turned up inside the regulated supply chain in the US, UK and Brazil (WHO and FDA alerts). And the cheap compounded workaround closed in 2025, when the FDA declared the semaglutide shortage over and a federal court declined to block that decision. Before paying list, the safe move is knowing every legitimate channel — the maker's own $349 cash page, the new Medicare pilot, and plan-by-plan coverage checks.

Frequently Asked Questions

How much does Wegovy cost in the US versus other countries?

Wegovy's US list price is $1,349.02 per four-week pack (Novo Nordisk), but the same company sells it self-pay for $349 a month on its own NovoCare site — since November 2025, with new patients paying $199 a month for their first two months on the starting doses (offer through December 31, 2026). Abroad, the maintenance dose costs about €277 a month in German pharmacies (patients pay it themselves), £73–176 a pack on the UK list (NHS patients who qualify pay only England's £9.90 prescription charge), and about $340 at the top dose in Denmark, Novo's home country. Same semaglutide, same maker.

Isn't Wegovy just expensive to make?

The maker's own pricing suggests otherwise. Novo sells the same pen self-pay for $349, and Lilly sells self-pay Zepbound (vial or KwikPen) for $299–449 with on-time refills — far under their ~$1,349 and ~$1,086 list prices. Peer-reviewed estimates put a sustainable, cost-based price — including a profit margin — at $0.89–$4.73 a month at the usual diabetes dose of semaglutide (Barber et al., JAMA Network Open 2024) and about $40 a month in a second study (Levi et al., Obesity 2023). The list price reflects the pricing system, not the chemistry.

Does insurance cover Wegovy or Zepbound for weight loss now?

Conditionally. On July 1, 2026 a Medicare pilot began covering Wegovy and the Zepbound KwikPen for weight loss at a $50 copay — the first time ever — but it's temporary (through the end of 2027), and the negotiated $385 Wegovy price doesn't start until January 2027. Outside Medicare, only about one in three of America's largest employers covered these drugs for weight loss in 2026 (KFF, down from 43% in 2025), and only 13 state Medicaid programs still did as of January 2026 (KFF).

Do other countries get a weaker version of the drug?

No — it's the same semaglutide from the same manufacturer, though in the UK and Denmark it comes as one four-dose pen instead of four single-dose pens. The difference is pricing, not the drug: Novo charges far less abroad even where public insurance doesn't pay (Germany excludes Wegovy as a lifestyle drug), while in the US list prices are high and the rebates insurers negotiate are confidential, so cash-pay patients feel the list price most. In 2023 data, Peterson-KFF found the US list price roughly 4.1× Germany's and 4.6× the Netherlands'.

Can Americans just order Wegovy or Zepbound from abroad?

It's rarely the clean shortcut it sounds like. The FDA says importing prescription drugs for personal use is illegal in most circumstances; it sometimes allows up to a 3-month supply, mainly when no effective treatment is available in the US — not the case for Wegovy or Zepbound — and packages can be seized. Counterfeit semaglutide (sold as Ozempic) has been found inside the regulated supply chain in the US, UK and Brazil (WHO, FDA). And the compounded-copy workaround closed in 2025, when the FDA declared the shortage over and a federal court declined to block that decision. Before paying list, the safe move is knowing every legitimate channel — including the maker's own $349 cash page.

Are GLP-1 prices coming down?

Directionally, yes. Novo's self-pay Wegovy price fell to $349 in November 2025, its list halves to $675 on January 1, 2027, Medicare-negotiated prices start the same day, and in April 2026 Canada approved the first generic semaglutide in the G7 — a copy of Ozempic for type 2 diabetes, not yet a weight-loss version. Presented strictly as cost data, not guidance — treatment decisions belong with a licensed prescriber.

Sources

Wellness Vision Editorial Policy

Wellness Vision does not sell medication, book trips, or receive referrals of any kind. The data comes from the public sources cited above. This is a cost comparison, not medical advice — nothing here tells anyone to start, stop, switch, or import a medication.

📋 Or get the free Medical Travel Cost Checklist — no email →

View provenance manifest for this video →

You shouldn't have to go broke to feel whole.

Wegovy: $1,349 Here, $349 on Novo's Own Site